Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 17/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.41 |
| ▸ | PRKACA | P17612 | 6/20 | 0.41 |
| ▸ | GSK3A | P49840 | 6/20 | 0.41 |
| ▸ | GSK3B | P49841 | 6/20 | 0.41 |
| ▸ | PRKG1 | Q13976 | 5/20 | 0.41 |
| ▸ | PRKX | P51817 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.41 |
| ▸ | SGK2 | Q9HBY8 | 4/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | AKT2 | P31751 | 3/20 | 0.41 |
| ▸ | PRKG2 | Q13237 | 3/20 | 0.41 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13035249 | 0.86 | PTGER4 (0.38) | CDK2CDK5DYRK1ADYRK3 | |
| SCHEMBL13035074 | 0.84 | PTGER4 (0.49) | — | |
| SCHEMBL13035070 | 0.84 | PTGER4 (0.36) | — | |
| SCHEMBL8191846 | 0.82 | GUCY1B2 (0.39) | MEN1KMT2ACDK2CYP3A4CYP2D6 | |
| SCHEMBL8199491 | 0.80 | PTGER4 (0.37) | KMT2A | |
| SCHEMBL8194184 | 0.80 | PTGER4 (0.37) | KMT2A | |
| SCHEMBL13035259 | 0.78 | MT-CO2 (0.36) | — | |
| SCHEMBL8192109 | 0.78 | PDPK1 (0.38) | — | |
| SCHEMBL13035264 | 0.77 | PTGER4 (0.36) | — | |
| SCHEMBL13035109 | 0.77 | PTGER4 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2008082490-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | ROCK1 868/4885MEN1 4216/4885KMT2A 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.